Skip to main content
Erschienen in:

26.11.2020 | Pancreatic Tumors

Association Between Neoadjuvant Chemoradiotherapy and Intractable Serous Ascites After Pancreaticoduodenectomy for Pancreatic Cancer

verfasst von: Atsushi Tomioka, MD, Tetsunosuke Shimizu, MD, PhD, Shuji Kagota, MD, PhD, Kohei Taniguchi, MD, PhD, Koji Komeda, MD, PhD, Mitsuhiro Asakuma, MD, PhD, Fumitoshi Hirokawa, MD, PhD, Kazuhisa Uchiyama, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Intractable serous (not chylous) ascites (IA) that infrequently develops early following pancreaticoduodenectomy (PD) for pancreatic cancer is a life-threatening problem. The relationship between neoadjuvant chemoradiotherapy (NACRT) for pancreatic cancer and the incidence of IA following PD has not been evaluated. This study aims to identify the risk factors associated with IA that develops early after PD for pancreatic cancer.

Methods

We retrospectively identified 94 patients who underwent PD for pancreatic cancer at the Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, Osaka, Japan, from April 2012 to March 2020. Data on 29 parameters were obtained from medical records. Univariate and multivariate analyses were conducted to identify independent risk factors. Levels of serum albumin were compared before and after NACRT to analyze its effect. Survival analysis was also conducted.

Results

Of the 92 patients included in this study, 8 (8.70%) were categorized into the IA group. Multivariate analysis identified NACRT [odds ratio (OR) 27, 95% confidence interval (CI) 1.87–394, p = 0.016)] and hypoalbuminemia (≤ 1.6 g/dl) just after the operation (OR 50, 95% CI 1.68–1516, p = 0.024) as risk factors. The level of serum albumin was significantly decreased following NACRT. The IA group had poorer prognosis than the control group.

Conclusions

IA is a serious problem that aggravates patient’s prognosis. Postoperative lymphatic leak might be a trigger of IA. NACRT was a major risk factor, followed by hypoalbuminemia caused by various reasons. These factors may act synergistically and cause IA.
Literatur
1.
Zurück zum Zitat Weniger M, D’Haese JG, Angele MK, et al. Treatment options for chylous ascites after major abdominal surgery: a systematic review. Am J Surg. 2016;211:206–13.CrossRef Weniger M, D’Haese JG, Angele MK, et al. Treatment options for chylous ascites after major abdominal surgery: a systematic review. Am J Surg. 2016;211:206–13.CrossRef
2.
Zurück zum Zitat Kuboki S, Shimizu H, Yoshidome H, et al. Chylous ascites after hepatopancreatobiliary surgery. Br J Surg. 2013;100:522–7.CrossRef Kuboki S, Shimizu H, Yoshidome H, et al. Chylous ascites after hepatopancreatobiliary surgery. Br J Surg. 2013;100:522–7.CrossRef
3.
Zurück zum Zitat Assumpcao L, Cameron JL, Wolfgang CL, et al. Incidence and management of chyle leaks following pancreatic resection: a high volume single-center institutional experience. J Gastrointest Surg. 2008;12:1915–23.CrossRef Assumpcao L, Cameron JL, Wolfgang CL, et al. Incidence and management of chyle leaks following pancreatic resection: a high volume single-center institutional experience. J Gastrointest Surg. 2008;12:1915–23.CrossRef
4.
Zurück zum Zitat Singh H, Pandit N, Krishnamurthy G, et al. Management of chylous ascites following pancreaticobiliary surgery. JGH Open. 2019;3:425–8.CrossRef Singh H, Pandit N, Krishnamurthy G, et al. Management of chylous ascites following pancreaticobiliary surgery. JGH Open. 2019;3:425–8.CrossRef
5.
Zurück zum Zitat Pabst TS, McIntyre KE, Schilling JD, et al. Management of chyloperitoneum after abdominal aortic surgery. Am J Surg. 1993;166:194–8.CrossRef Pabst TS, McIntyre KE, Schilling JD, et al. Management of chyloperitoneum after abdominal aortic surgery. Am J Surg. 1993;166:194–8.CrossRef
6.
Zurück zum Zitat Tabchouri N, Frampas E, Marques F, et al. Chylous ascites management after pancreatic surgery. World J Surg. 2017;41:1054–60.CrossRef Tabchouri N, Frampas E, Marques F, et al. Chylous ascites management after pancreatic surgery. World J Surg. 2017;41:1054–60.CrossRef
7.
Zurück zum Zitat 7. Van der Gaag NA, Verhaar AC, Haverkort EB, et al. Chylous ascites after pancreaticoduodenectomy: introduction of a grading system. J Am Coll Surg. 2008;207:751–7.CrossRef 7. Van der Gaag NA, Verhaar AC, Haverkort EB, et al. Chylous ascites after pancreaticoduodenectomy: introduction of a grading system. J Am Coll Surg. 2008;207:751–7.CrossRef
8.
Zurück zum Zitat Kaas R, Rustman LD, Zoetmulder FA. Chylous ascites after oncological abdominal surgery: incidence and treatment. Eur J Surg Oncol. 2001;27:187–9.CrossRef Kaas R, Rustman LD, Zoetmulder FA. Chylous ascites after oncological abdominal surgery: incidence and treatment. Eur J Surg Oncol. 2001;27:187–9.CrossRef
9.
Zurück zum Zitat Strobel O, Brangs S, Hinz U, et al. Incidence, risk factors and clinical implications of chyle leak after pancreatic surgery. Br J Surg. 2017;104:108–17.CrossRef Strobel O, Brangs S, Hinz U, et al. Incidence, risk factors and clinical implications of chyle leak after pancreatic surgery. Br J Surg. 2017;104:108–17.CrossRef
10.
Zurück zum Zitat Verma V, Li J, Lin C. Neoadjuvant therapy for pancreatic cancer: systematic review of postoperative morbidity, mortality, and complications. Am J Clin Oncol. 2016;39:302–13.CrossRef Verma V, Li J, Lin C. Neoadjuvant therapy for pancreatic cancer: systematic review of postoperative morbidity, mortality, and complications. Am J Clin Oncol. 2016;39:302–13.CrossRef
11.
Zurück zum Zitat Versteijne E, van Eijck CH, Punt CJ, et al. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. Trials. 2016;17:127.CrossRef Versteijne E, van Eijck CH, Punt CJ, et al. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. Trials. 2016;17:127.CrossRef
12.
Zurück zum Zitat Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut. 2006;55(6):vi1–vi12. Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut. 2006;55(6):vi1–vi12.
14.
Zurück zum Zitat Ahmed S, Shaw G, Al Kadhi O. Massive ascites following robot-assisted radical prostatectomy and extended pelvic lymph node dissection: a case report. J Endourol Case Rep. 2019;5:139–41.CrossRef Ahmed S, Shaw G, Al Kadhi O. Massive ascites following robot-assisted radical prostatectomy and extended pelvic lymph node dissection: a case report. J Endourol Case Rep. 2019;5:139–41.CrossRef
15.
Zurück zum Zitat Pan W, Yang C, Cai S-Y et al. Incidence and risk factors of chylous ascites after pancreatic resection. Int J Clin Exp Med. 2015;8:4494–500.PubMedPubMedCentral Pan W, Yang C, Cai S-Y et al. Incidence and risk factors of chylous ascites after pancreatic resection. Int J Clin Exp Med. 2015;8:4494–500.PubMedPubMedCentral
16.
Zurück zum Zitat 16. Kojima M, Inoue M, Yamamoto S, et al. Successful treatment of hepatic lymphorrhea by percutaneous transhepatic lymphangiography followed by sclerotherapy using OK-432. Surg Case Rep. 2019;5:1–6.CrossRef 16. Kojima M, Inoue M, Yamamoto S, et al. Successful treatment of hepatic lymphorrhea by percutaneous transhepatic lymphangiography followed by sclerotherapy using OK-432. Surg Case Rep. 2019;5:1–6.CrossRef
17.
Zurück zum Zitat Tanaka K, Ohmori Y, Mohri Y, et al. Successful treatment of refractory hepatic lymphorrhea after gastrectomy for early gastric cancer, using surgical ligation and subsequent OK-432 (picibanil) sclerotherapy. Gastric Cancer. 2004;7:117–21.CrossRef Tanaka K, Ohmori Y, Mohri Y, et al. Successful treatment of refractory hepatic lymphorrhea after gastrectomy for early gastric cancer, using surgical ligation and subsequent OK-432 (picibanil) sclerotherapy. Gastric Cancer. 2004;7:117–21.CrossRef
18.
Zurück zum Zitat Aalami OO, Allen DB, Organ CH Jr. Chylous ascites: a collective review. Surgery. 2000;128:761–78.CrossRef Aalami OO, Allen DB, Organ CH Jr. Chylous ascites: a collective review. Surgery. 2000;128:761–78.CrossRef
19.
Zurück zum Zitat Kwon S, Janssen CF, Velasquez FC, et al. Radiation dose-dependent changes in lymphatic remodeling. Int J Radiat Oncol Biol Phys. 2019;105:852–60.CrossRef Kwon S, Janssen CF, Velasquez FC, et al. Radiation dose-dependent changes in lymphatic remodeling. Int J Radiat Oncol Biol Phys. 2019;105:852–60.CrossRef
20.
Zurück zum Zitat Baselet B, Sonveaux P, Baatout S, et al. Pathological effects of ionizing radiation: endothelial activation and dysfunction. Cell Mol Life Sci. 2019;76:699–728.CrossRef Baselet B, Sonveaux P, Baatout S, et al. Pathological effects of ionizing radiation: endothelial activation and dysfunction. Cell Mol Life Sci. 2019;76:699–728.CrossRef
21.
Zurück zum Zitat Jørgensen MG, Toyserkani NM, Hansen CR, et al. Quantification of chronic lymphedema in a revised mouse model. Ann Plast Surg. 2018;81:594–603.CrossRef Jørgensen MG, Toyserkani NM, Hansen CR, et al. Quantification of chronic lymphedema in a revised mouse model. Ann Plast Surg. 2018;81:594–603.CrossRef
24.
Zurück zum Zitat Sim EH, Kwon JH, Kim SY, et al. Severe steatohepatitis with hepatic decompensation resulting from malnutrition after pancreaticoduodenectomy. Clin Mol Hepatol. 2012;18:404–10.CrossRef Sim EH, Kwon JH, Kim SY, et al. Severe steatohepatitis with hepatic decompensation resulting from malnutrition after pancreaticoduodenectomy. Clin Mol Hepatol. 2012;18:404–10.CrossRef
25.
Zurück zum Zitat Song SC, Choi SH, Choi DW, et al. Potential risk factors for nonalcoholic steatohepatitis related to pancreatic secretions following pancreaticoduodenectomy. World J Gastroenterol. 2011;17(32):3716–23.CrossRef Song SC, Choi SH, Choi DW, et al. Potential risk factors for nonalcoholic steatohepatitis related to pancreatic secretions following pancreaticoduodenectomy. World J Gastroenterol. 2011;17(32):3716–23.CrossRef
26.
Zurück zum Zitat Kang CM, Lee JH. Pathophysiology after pancreaticoduodenectomy. World J Gastroenterol. 2015;21:5794–804.CrossRef Kang CM, Lee JH. Pathophysiology after pancreaticoduodenectomy. World J Gastroenterol. 2015;21:5794–804.CrossRef
Metadaten
Titel
Association Between Neoadjuvant Chemoradiotherapy and Intractable Serous Ascites After Pancreaticoduodenectomy for Pancreatic Cancer
verfasst von
Atsushi Tomioka, MD
Tetsunosuke Shimizu, MD, PhD
Shuji Kagota, MD, PhD
Kohei Taniguchi, MD, PhD
Koji Komeda, MD, PhD
Mitsuhiro Asakuma, MD, PhD
Fumitoshi Hirokawa, MD, PhD
Kazuhisa Uchiyama, MD, PhD
Publikationsdatum
26.11.2020
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 7/2021
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-09401-w

Neu im Fachgebiet Chirurgie

Hochrisiko-Spinaliom am besten mit der Mohs-Chirurgie entfernen

Die Mohs-Chirurgie ist zwar mit mehr Aufwand verbunden als die herkömmliche Exzision; für die Versorgung kutaner Hochrisiko-Plattenepithelkarzinome lohnt sich die zeitintensive Technik aber in jedem Fall. Laut einer aktuellen Studie sinkt im Vergleich das Sterberisiko.

Darmpolyp weg – Peptid-Gel gegen Nachblutungen drauf?

Das Nachblutungsrisiko nach einer endoskopischen Mukosaresektion von flachen kolorektalen und duodenalen Adenomen war in der deutschen PURPLE-Studie mit einem hämostatischen Gel nicht kleiner als ohne Prophylaxe.

Krebs-Op. besser erst nach mehrwöchigem Rauchverzicht?

Aktive Raucher haben nach onkologischen Operationen ein höheres Komplikationsrisiko als Nieraucher, aber auch als Exraucher. Damit der Rauchstopp einen Nutzen hat, darf er aber nicht zu kurz vor der Op. erfolgen, wie eine Metaanalyse nahelegt.

Periprozeduraler Myokardschaden nach NSTEMI prognostisch bedeutsam

Erleiden NSTEMI-Patienten und -Patientinnen infolge einer PCI Myokardschädigungen mit oder ohne Infarkt, erhöht das die Gesamtmortalität und das Risiko für weitere schwere Herzereignisse. Dafür sprechen zumindest Daten aus zwei italienischen Zentren.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.